Beijing Biostar Pharmaceuticals (HKG:2563) launched its initial public offering in Hong Kong, seeking to raise as much as HK$320.9 million.
The pharmaceutical is offering 14,588,000 H shares at HK$16 to HK$22 apiece.
Beijing Biostar secured Novotech SG, Baheal Wellness, SilkyWater Absolute Return, and Wealth Strategy as cornerstone investors, which committed to subscribe for HK$178.8 million worth of IPO shares.
The issuer expects to determine its offer price on Oct. 29 and disclose the allocations on Oct. 30. It will then start trading on the Hong Kong bourse on Oct. 31, according to a Wednesday filing.
Net proceeds, estimated at HK$234 million, will be used to fund core products, clinical trials, and studies for non-core products and construct a local and international marketing network. Some of the funds will also be used to enhance production capabilities, and the rest will be used for general working capital needs.
CCB International, China Securities International, ICBC, SPDB International, and several others are the joint book-runners of the IPO.
Price (HKD): $2761.00, Change: $+1.2, Percent Change: +0.04%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。